These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. A Novel KIT INDEL Mutation in Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1. Lee JH; Park C; Kim SH; Shin MG Ann Lab Med; 2016 Jul; 36(4):371-4. PubMed ID: 27139612 [No Abstract] [Full Text] [Related]
10. [Prognostic value of dynamic monitoring of RUNX1-RUNX1T1 transcript in pediatric acute myeloid leukemia]. Gao HT; Zhang Y; Sun K; Guo JM; Chen YQ; Chen XL; Shi J; Niu XN; Wang F; Huo L Zhonghua Xue Ye Xue Za Zhi; 2017 Mar; 38(3):210-215. PubMed ID: 28395444 [No Abstract] [Full Text] [Related]
11. In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification. Wang Y; Wu DP; Liu QF; Qin YZ; Wang JB; Xu LP; Liu YR; Zhu HH; Chen J; Dai M; Huang XJ Blood; 2014 Sep; 124(12):1880-6. PubMed ID: 25082877 [TBL] [Abstract][Full Text] [Related]
12. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay. Marcucci G; Livak KJ; Bi W; Strout MP; Bloomfield CD; Caligiuri MA Leukemia; 1998 Sep; 12(9):1482-9. PubMed ID: 9737700 [TBL] [Abstract][Full Text] [Related]
13. Acute myeloid leukemia (AML) with t(8;21)(q22;q22) relapsing as AML with t(3;21)(q26;q22). Bacher U; Schnittger S; Kern W; Trenn G; Weisser M; Haferlach T; Schoch C Cancer Genet Cytogenet; 2006 Jul; 168(2):172-4. PubMed ID: 16843110 [TBL] [Abstract][Full Text] [Related]
14. Quantification of AML1-ETO fusion transcript as a prognostic indicator in acute myeloid leukemia. Yoo SJ; Chi HS; Jang S; Seo EJ; Seo JJ; Lee JH; Park HS; Park CJ Haematologica; 2005 Nov; 90(11):1493-501. PubMed ID: 16266896 [TBL] [Abstract][Full Text] [Related]
15. A new complex translocation t(8;11;21)(q22;q24;q22) in acute myeloid leukemia with RUNX1/RUNX1T1. Yamamoto K; Yakushijin K; Funakoshi Y; Sanada Y; Kawamoto S; Matsuoka H; Minami H J Clin Exp Hematop; 2014; 54(2):167-70. PubMed ID: 25318951 [No Abstract] [Full Text] [Related]
16. Monitoring of minimal residual disease in acute myeloid leukemia with t(8;21)(q22;q22). Zhang L; Li Q; Li W; Liu B; Wang Y; Lin D; Zhou C; Li C; Wang J; Mi Y Int J Hematol; 2013 Jun; 97(6):786-92. PubMed ID: 23613269 [TBL] [Abstract][Full Text] [Related]
17. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia. Scholl C; Schlenk RF; Eiwen K; Döhner H; Fröhling S; Döhner K; Haematologica; 2005 Dec; 90(12):1626-34. PubMed ID: 16330435 [TBL] [Abstract][Full Text] [Related]
18. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Tobal K; Newton J; Macheta M; Chang J; Morgenstern G; Evans PA; Morgan G; Lucas GS; Liu Yin JA Blood; 2000 Feb; 95(3):815-9. PubMed ID: 10648391 [TBL] [Abstract][Full Text] [Related]
19. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Ommen HB; Schnittger S; Jovanovic JV; Ommen IB; Hasle H; Østergaard M; Grimwade D; Hokland P Blood; 2010 Jan; 115(2):198-205. PubMed ID: 19901261 [TBL] [Abstract][Full Text] [Related]
20. Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan. Narimatsu H; Iino M; Ichihashi T; Yokozawa T; Hayakawa M; Kiyoi H; Takeo T; Sawamoto A; Iida H; Tsuzuki M; Yanada M; Naoe T; Suzuki R; Sugiura I Int J Hematol; 2008 Sep; 88(2):154-158. PubMed ID: 18553224 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]